Adecoagro S A Com (AGRO) Shareholder Sloane Robinson Llp Trimmed Its Stake by $361,000; Eagle Pharmaceuticals (EGRX) Holding Maintained by Iridian Asset Management Llc

January 14, 2018 - By Ellis Scott

David Cohen increased its stake in Eagle Pharmaceuticals (EGRX) by 17.17% based on its latest 2017Q3 regulatory filing with the SEC. Iridian Asset Management Llc bought 119,327 shares as the company’s stock rose 7.49% with the market. The hedge fund run by David Cohen held 814,214 shares of the health care company at the end of 2017Q3, valued at $48.56M, up from 694,887 at the end of the previous reported quarter. Iridian Asset Management Llc who had been investing in Eagle Pharmaceuticals for a number of months, seems to be bullish on the $926.48 million market cap company. The stock decreased 0.75% or $0.47 during the last trading session, reaching $62.09. About 319,808 shares traded or 22.30% up from the average. Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) has risen 79.40% since January 14, 2017 and is uptrending. It has outperformed by 62.70% the S&P500.

Hugh Sloane decreased its stake in Adecoagro S A Com (AGRO) by 20.68% based on its latest 2017Q3 regulatory filing with the SEC. Sloane Robinson Llp sold 36,100 shares as the company’s stock declined 12.17% while stock markets rallied. The hedge fund run by Hugh Sloane held 138,500 shares of the farming and seeds and milling company at the end of 2017Q3, valued at $1.50 million, down from 174,600 at the end of the previous reported quarter. Sloane Robinson Llp who had been investing in Adecoagro S A Com for a number of months, seems to be less bullish one the $1.23B market cap company. The stock increased 1.10% or $0.11 during the last trading session, reaching $10.12. About 436,981 shares traded. Adecoagro S.A. (NYSE:AGRO) has risen 9.46% since January 14, 2017 and is uptrending. It has underperformed by 7.24% the S&P500.

Among 4 analysts covering Eagle Pharma (NASDAQ:EGRX), 3 have Buy rating, 1 Sell and 0 Hold. Therefore 75% are positive. Eagle Pharma had 20 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Thursday, October 26 by Mizuho. As per Wednesday, August 9, the company rating was maintained by Piper Jaffray. The rating was downgraded by Mizuho on Wednesday, November 16 to “Neutral”. RBC Capital Markets maintained Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Sunday, November 5 with “Buy” rating. The company was maintained on Monday, December 18 by Mizuho. Mizuho downgraded Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) on Monday, January 9 to “Underperform” rating. Mizuho maintained it with “Buy” rating and $62 target in Wednesday, October 26 report. The company was maintained on Friday, February 26 by Mizuho. The firm has “Sell” rating given on Wednesday, August 9 by Mizuho. The stock of Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) earned “Buy” rating by RBC Capital Markets on Friday, September 1.

Iridian Asset Management Llc, which manages about $11.52B and $11.71B US Long portfolio, decreased its stake in Blackberry Ltd (NASDAQ:BBRY) by 2.46 million shares to 20.30M shares, valued at $226.96 million in 2017Q3, according to the filing. It also reduced its holding in Dcp Midstream Partners Lp (NYSE:DPM) by 87,340 shares in the quarter, leaving it with 36,565 shares, and cut its stake in Intrexon Corp (NYSE:XON).

Among 3 analysts covering Adecoagro S.A. (NYSE:AGRO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adecoagro S.A. had 4 analyst reports since September 28, 2015 according to SRatingsIntel. Morgan Stanley maintained the shares of AGRO in report on Monday, November 23 with “Overweight” rating. Bank of America upgraded the shares of AGRO in report on Tuesday, December 15 to “Buy” rating. The stock has “Overweight” rating by JP Morgan on Monday, September 28.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>